The Heart Stent Procedure (Percutaneous Coronary Intervention): A Comprehensive Guide

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers before starting new treatments and for all medical decisions. Never delay seeking medical care based on content you have read.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief: When Does a Heart Stent Actually Help?

Finding a coronary blockage does not automatically mean it needs to be opened with a stent. Whether stenting helps — and how much — depends on whether the blockage is actively causing a heart attack, limiting blood flow enough to produce ischaemia, causing symptoms that persist despite medical therapy, or involving anatomy that carries prognostic risk beyond what medications can address. For some patients in some situations, stenting is lifesaving. For others in stable disease, medications provide equivalent protection with less procedural risk. The difference between these situations — and how cardiologists reason through them — is what this article explains.

---

A Blockage Is Not Automatically a Problem to Fix

This is the most important concept in the article, and it belongs at the beginning.

When patients hear “you have a coronary blockage,” the instinct is powerful and natural: something is blocked, something must be unblocked. Plumbing logic. Find the obstruction, remove it, problem solved.

Modern cardiology works differently. Many years of evidence — including large randomised trials that genuinely surprised the medical community — have established that opening a coronary narrowing with a stent does not always change what happens to the patient long-term. In stable coronary disease, the risk of future heart attack is often driven not by the specific blocked segment but by biological processes distributed throughout the entire vascular system: inflammation, plaque instability, thrombosis tendency, LDL accumulation, and metabolic dysfunction. Fixing one narrowed segment does not alter those processes elsewhere.

This is not a reason to dismiss stenting. A stent can be lifesaving in a heart attack. It can dramatically improve quality of life in a patient with limiting angina. It is the right treatment in specific, definable situations.[34] The challenge in modern cardiology is not “to stent or not to stent” — it is identifying which specific combination of anatomy, physiology, symptoms, and biology justifies a procedure beyond what optimised systemic therapy achieves.

That is the central question this article answers.

---

CAD Is Two Problems, Not One: Focal Anatomy vs. Systemic Biology

Understanding coronary stenting requires understanding that coronary artery disease is actually two distinct problems that require two distinct solutions.

The focal anatomy problem involves mechanical obstruction and localized blood flow deprivation:

• Vessel narrowing: Atherosclerotic plaque physically restricts the arterial lumen at a specific geographic segment.
• Myocardial ischemia: Downstream heart muscle becomes oxygen-deprived, characteristically inducing symptoms like angina, exertional breathlessness, and acute exercise intolerance.
• Acute plaque rupture: In its most severe presentation, an unstable plaque ruptures, triggering immediate thrombus (clot) formation that completely occludes the artery and initiates a time-dependent heart attack.

The systemic biology problem represents a widespread disease process across the entire vascular system:

• Diffuse plaque distribution: Atherosclerosis is inherently distributed throughout the entire coronary tree, hiding within angiographically “normal” or non-obstructive segments.
• Systemic drivers: The disease is actively propelled by global metabolic and vascular dysfunctions, including elevated LDL particle accumulation, chronic vascular inflammation, endothelial injury, and baseline thrombotic tendencies.
• Focal treatment limits: Because these pathologic processes are distributed globally, treating a single localized segment with a mechanical device cannot alter the biological risks present elsewhere in the system.

PCI treats the first problem. Medications treat the second.

A stent restores blood flow through one narrowed segment. It cannot lower ApoB throughout the vascular system. It cannot reduce inflammation in plaques it did not touch. It cannot modify thrombosis risk in the coronary tree it did not reach. Medications do these things — and they do them systemically, affecting every plaque in every segment.

This is why, in stable coronary disease, large randomised trials found that patients treated with optimal medications alone had similar rates of death and heart attack as those who received stents plus medications.[5,6] The procedures treated the anatomy effectively. They left the biology unchanged.

And this is why, in a heart attack, a stent is often lifesaving: one specific artery is acutely occluded, and opening it stops ongoing myocardial injury. The focal anatomy problem has become an emergency. Addressing it promptly matters.

Many future heart attacks arise from plaques that were not severely obstructive beforehand. The PROSPECT natural history study tracked patients after heart attack and followed the condition of all their coronary plaques prospectively. A substantial proportion of subsequent events arose from lesions that were not flow-limiting at baseline — plaques that were biologically unstable but not anatomically prominent.[8] This is why treating one blockage does not eliminate future risk. The biology that created that plaque is still operating throughout the coronary tree.

---

Two Types of Risk: Symptom Burden vs. Prognostic Risk

One of the most consistent sources of confusion about coronary stenting is that patients conflate two genuinely different things: how bad symptoms are, and how dangerous the disease is.

Risk Type	What It Measures	What It Determines
Symptom burden	How much angina limits daily life	Quality of life; indication for symptom-targeted treatment
Prognostic risk	Likelihood of MI, heart failure, or death	Need for prognosis-modifying therapy

This distinction is established by the stable CAD trial evidence (COURAGE[5], ISCHEMIA[6]) and the appropriate use criteria framework.[34] It is an editorial synthesis of those sources.

These two dimensions are related but not the same — and this matters enormously for stenting decisions.

A patient can have severe, frequent angina from a single significant narrowing, with high symptom burden but relatively preserved long-term prognosis if medications are optimised. A stent here improves quality of life substantially. It may or may not change survival. A different patient can have minimal symptoms but high-risk anatomy — left main disease, severely reduced ventricular function, ischaemia in a large territory — where revascularisation has clearer prognostic benefit regardless of symptom severity.

Severe symptoms do not always mean severe danger. A flow-limiting obstruction producing daily angina may not be the lesion most likely to cause a heart attack. Plaque instability is determined by biology — the thickness of the fibrous cap, the size of the inflammatory lipid core — not by how much the lumen is narrowed.

Minimal symptoms do not always mean low risk. Some of the most dangerous coronary anatomy — left main disease, proximal multivessel disease — can exist for years without prominent symptoms.

Understanding this separation is what allows the rest of this article to make sense.

---

What Is a Heart Stent and How Does a Heart Stent Work?

With the conceptual framework established, understanding the heart stent procedure becomes deeply meaningful. A coronary stent is a small, expandable mesh tube — typically metal, typically coated with a slow-releasing medication — that holds open a narrowed heart artery. If you wonder how does a heart stent works, it functions by mechanically expanding inside the vessel where atherosclerotic plaque has compromised blood flow, acting as a permanent internal scaffold to restore myocardial perfusion.

Clinically, this intervention is known as Percutaneous Coronary Intervention (PCI) — “percutaneous” meaning through the skin, rather than through an open incision in the chest. During this process, a thin catheter is advanced through a small puncture in the wrist (radial access) or groin (femoral access), traveling through the arterial tree directly to the epicardial coronary vessels. At the blockage, a balloon is inflated to compress the plaque against the arterial wall; the stent, mounted on the balloon, expands into place. The balloon is removed. The stent remains permanently, acting as internal scaffolding.

A stent also creates a medication obligation. The metal scaffold, before it is covered by healed arterial tissue, has a surface that promotes platelet aggregation. This is why stenting requires ongoing dual antiplatelet therapy — to prevent clot formation on the healing stent surface. A stent solves a flow problem and creates a medication requirement that needs to be managed consistently.

A note on scope: not all chest pain or heart attacks arise from atherosclerotic plaque. Some arise from coronary artery spasm, spontaneous coronary artery dissection (SCAD), myocarditis, or microvascular disease — situations where stenting may not help and can sometimes cause harm. Diagnosis determines the pathway. This article addresses atherosclerotic CAD, where stenting has an established role.

---

How Cardiologists Decide Whether Percutaneous Coronary Intervention (PCI) Helps

The clinical decision to recommend or decline a stent in a given patient reflects a sequence of questions. Understanding this sequence is more useful than any specific fact about any specific trial.

Question 1: Is this an emergency? Is a coronary artery acutely occluded or severely threatened? Is heart muscle being actively injured right now? If yes — STEMI, high-risk NSTEMI, haemodynamically unstable ACS — the calculus shifts decisively toward immediate intervention. Delaying costs myocardium. Opening the artery is the priority.

Question 2: If stable, is the blockage truly flow-limiting? Angiography shows the appearance of a narrowing. It does not reliably show whether blood flow through that segment is actually impaired. A narrowing that looks severe on X-ray may permit adequate flow; a moderate-appearing narrowing may significantly restrict it. Physiologic testing — FFR (fractional flow reserve) or iFR (instantaneous wave-free ratio) — measures the pressure gradient across a lesion to determine whether it is actually impeding flow. Stenting a non-flow-limiting lesion improves neither symptoms nor outcomes.[15] This is why a 60% or 70% narrowing does not automatically warrant a stent.

Question 3: Are symptoms present and limiting? Even a flow-limiting lesion may not need treatment if symptoms are absent or well-controlled. The question is whether the patient is suffering sufficiently that symptom relief justifies procedural risk and the DAPT obligation — and whether medical therapy has genuinely been optimised first.

Question 4: Does the anatomy carry prognostic risk beyond what medications address? Certain anatomical situations carry risk that justifies revascularisation for prognosis, not just symptoms: significant left main coronary artery disease (which supplies the bulk of the left ventricle), severe multivessel disease with reduced ventricular function, and large territory ischaemia in some settings. These are situations where the anatomy itself — not just current symptoms — drives the decision.

Question 5: Is PCI the right revascularisation strategy, or should bypass surgery be considered? When evaluating the long-term clinical data of heart bypass surgery vs stents for complex multivessel disease—especially in patients with concurrent diabetes or reduced ventricular function—surgical bypass consistently provides more durable revascularization and superior long-term survival metrics. The choice between PCI and CABG is its own decision, addressed separately below.

Question 6: Can the patient safely sustain the required medications? Sustaining Dual Antiplatelet Therapy After Drug-eluting Stent implantation is an absolute clinical requirement. Patients must understand that prematurely stopping blood thinners after a stent leaves the underlying metallic scaffold exposed to platelets, drastically increasing the risk of catastrophic vessel re-occlusion.

Question 7: What does the patient understand and prefer? For stable disease where multiple reasonable options exist, shared decision-making is not bureaucratic courtesy — it is clinically appropriate. The evidence in stable CAD often supports either pathway; patient values, lifestyle, and informed preference legitimately influence the final decision.

This seven-question framework organises everything that follows.

What problem are we trying to solve? Different clinical situations call for fundamentally different answers:

Concept	Why It Matters	What It Determines
STEMI	Active myocardial death — minutes matter	Immediate reperfusion; often lifesaving
High-risk NSTEMI	Unstable plaque and thrombosis actively occurring	Event reduction in appropriate patients
Stable angina — confirmed ischaemia	Symptoms limiting quality of life	Symptom relief; not routine event prevention
Left main disease	Large myocardial territory at risk	Prognostic benefit; heart team decision
Multivessel disease with diabetes	Long-term event burden; diffuse biology	Often CABG-favoured
Non-flow-limiting lesion	Appearance only — no physiologic significance	Usually medical therapy; stenting adds risk without benefit

Keeping this table in mind as you read the evidence below makes the trial results and guideline recommendations much more intuitive.

---

Emergency PCI: Treating Heart Attacks and Acute Coronary Syndrome

In a heart attack, the clinical situation is fundamentally different from stable CAD. One artery — the culprit vessel — is completely or near-completely occluded, typically by a blood clot that has formed on a ruptured plaque. Heart muscle in the territory supplied by that artery is dying. The rate of death is time-dependent: every minute of sustained occlusion converts viable, reversible ischaemia into permanent scar. Opening the artery quickly limits the damage and saves lives.[1,2]

This is the situation where stenting is most clearly lifesaving. The focal anatomy problem has become acute. The systemic biology problem remains — it will need to be addressed with medications long-term — but right now, the overwhelming priority is restoring flow.

STEMI (ST-elevation myocardial infarction) represents complete or near-complete occlusion of a coronary artery. Primary PCI — opening the artery with a balloon and stent — is the preferred treatment when it can be delivered quickly by an experienced team. In systems with rapid access to a catheterisation laboratory, primary PCI reduces mortality and limits infarct size compared to thrombolytic therapy.[1,2]

Non-ST-Elevation Myocardial Infarction (NSTEMI) and unstable angina represent high-risk, fluid clinical states:

• Intermittent obstruction: The culprit coronary artery experiences partial or transient blockages, meaning some baseline blood flow persists but remains highly vulnerable.
• Active plaque disruption: The core biological triggers of a massive heart attack—including local plaque rupture and active clot formation—are already underway.
• Early invasive management: Clinical guidelines advocate for coronary catheterization within 24 to 72 hours to stent culprit lesions, which significantly reduces secondary events in patients exhibiting elevated troponins, dynamic ECG changes, or hemodynamic instability.

What the emergency experience feels like. Patients who have had emergency stenting often describe the experience as a whirlwind: one moment life was normal, the next they were on a table with strangers working on their heart. Consent is often brief, sometimes with family present, under genuine time pressure. The explanations come afterward — because in STEMI care, the only explanation that matters first is opening the artery. The chaos is not a sign of poor care; it reflects appropriate urgency. Every minute matters.

For family members: the wait during emergency PCI is genuinely difficult. Limited information in the waiting area usually means the team is focused on the procedure. The full conversation typically happens after the patient is stable.

---

Heart Stents for Stable Angina: What the Clinical Evidence Shows

Before 2007, many cardiologists — and most patients — operated on an assumption that seemed intuitively obvious: open a significant blockage, reduce the risk of future heart attack. The mechanical metaphor felt compelling. Atherosclerosis was understood as plaque-in-pipes, and clearing a pipe seemed like it should reduce downstream events.

Two landmark trials forced cardiology to confront how much of that assumption was wrong for stable disease.

COURAGE (2007) randomised over 2,000 patients with stable CAD and significant blockages to PCI plus optimal medical therapy versus optimal medical therapy alone. After nearly five years, death and heart attack rates were similar in both groups.[5] Both groups did well. The stented patients had faster symptom relief — but the systemic event risk was driven by biology, not by which segments had been mechanically opened.

ISCHEMIA (2020) extended this further — over 5,000 patients with stable CAD and moderate-to-severe ischaemia on stress testing, randomised to initial invasive strategy versus conservative medical management. No overall reduction in cardiovascular death or MI with the initial invasive strategy in the stable cohort. Quality of life benefits were greatest in patients with frequent limiting angina.[6] Notably, ISCHEMIA specifically excluded significant left main disease — a category where revascularisation has clearer prognostic benefit.

The landmark data from COURAGE and ISCHEMIA challenged deeply entrenched clinical assumptions:

• The plumbing myth: Opening a mechanical narrowing in a stable patient does not automatically lower long-term mortality or prevent future heart attacks.
• Unpredictable culprit lesions: Future cardiac events frequently originate from non-obstructive, mild plaques that were completely bypassed during initial imaging because they were not flow-limiting at baseline.
• The biological priority: The overall systemic environment—such as background inflammation and plaque instability—dictates long-term prognosis far more than the cross-sectional percentage of any single arterial narrowing.

This was a genuine intellectual revolution in cardiology. It did not make stenting less important — it clarified whenstenting changes outcomes and when it does not.

The ORBITA trial (2018) added nuance to the symptom question. Patients with stable single-vessel angina were randomised to PCI versus a sham procedure — catheterisation without stenting. Both groups improved; the difference between them was smaller than expected.[7] This suggests that some of the perceived symptom benefit from PCI includes expectation and contextual effects beyond pure physiology. It does not imply angina is imagined, and it does not apply to ACS. But it reinforces the importance of confirming that ischaemia is truly the driver of symptoms before proceeding with stenting primarily for symptom relief.

What this evidence means in practice. Utilizing heart stents for stable angina serves primarily as a target for symptom relief and improving quality of life — not as a routine preventative measure for extending survival. The patients who benefit most from stenting are those with frequent, limiting angina that persists despite optimized medical therapy, accompanied by clear, objective evidence of ischemia in the territory of the treated vessel. For patients with mild symptoms, excellent exercise tolerance, or well-controlled angina on medications, the incremental benefit of stenting is often small.

This does not mean medical therapy in stable CAD is “doing nothing.” High-intensity statin therapy, antiplatelet agents, blood pressure control, and comprehensive risk factor management are the primary event-prevention strategy. They are active, evidence-based treatment of the systemic biology — the part of the disease that actually determines most of the long-term risk.

Why medical therapy feels psychologically unsatisfying — even when it is the right choice — is worth naming directly. A stent produces a visible, definitive mechanical act. A cardiologist can show you a before-and-after angiogram. Medications produce no sensation, no image, no moment of completion. Yet in stable CAD, the medications are doing more for long-term outcomes than the procedure. This is one of the most counterintuitive aspects of modern cardiovascular care, and it explains why patients sometimes feel they are “not being treated” when medications are chosen over stenting. They are being treated — for the part of the disease that matters most.

---

What PCI Can and Cannot Fix

PCI Can	PCI Cannot
Restore blood flow through a specific treated narrowing	Modify plaque biology throughout the coronary tree
Relieve ischaemic angina from a flow-limiting lesion	Prevent events arising from untreated plaques elsewhere
Limit infarct size and save lives in STEMI	Replace medications — DAPT becomes a new requirement
Improve outcomes in selected high-risk anatomy	Cure coronary artery disease
Improve quality of life in limiting stable angina	Reliably eliminate future events in stable disease

Evidence basis: COURAGE[5], ISCHEMIA[6], PROSPECT[8]; ACS outcome data[1,2,3,4].

The common misunderstanding after a “successful” stent is that the disease has been fixed. A technically perfect procedure — full stent expansion, excellent flow, no complications — leaves the systemic biology unchanged. Inflammation, lipoprotein burden, metabolic dysfunction, and endothelial injury throughout the vascular system are not addressed by opening one segment. This is not a criticism of the procedure. It is a description of what the procedure actually does.

Technical success ≠ clinical success. Technical success means the artery was opened, the stent was well-deployed, flow was restored. Clinical success means symptoms improved, future risk was reduced, function was preserved, and the therapeutic obligations created by the stent were manageable. These are related but genuinely different outcomes.

---

Why Would a Doctor Not Put a Stent In?

This is often the most emotionally difficult concept for patients — being told a visible blockage will be managed without a procedure. Understanding why helps.

The narrowing is not flow-limiting. A blockage that looks moderate or significant on angiography may not actually restrict blood flow enough to cause ischaemia. If physiologic testing (FFR or iFR) confirms adequate flow, stenting that lesion does not improve symptoms or outcomes.[15] The appearance was more dramatic than the physiology. This is precision medicine — not undertreating.

Symptoms are controlled. If a patient has a flow-limiting lesion but angina is well-controlled with medications and functional capacity is preserved, adding stenting adds procedural risk without clear benefit. The question is not “can we stent this?” but “does stenting improve the patient’s life or prognosis enough to justify the risks?”

The disease is diffuse. When plaque is distributed throughout the artery length rather than concentrated in a focal segment, stenting one portion does not address the broader pattern. Diffuse disease may be better managed medically, or sometimes with bypass surgery that can route blood around longer diseased segments.

Anatomy is unfavourable. Very small vessels, heavily calcified lesions in certain locations, or certain anatomical configurations have lower procedural success rates and higher complication rates. The risk-benefit balance may favour medical therapy.

Bypass surgery offers better outcomes. For complex multi-vessel disease — particularly in patients with diabetes or significantly reduced ventricular function — bypass surgery provides more complete and durable revascularisation. Recommending CABG over PCI is not a sign that the disease is hopeless; it is a sign that the anatomy calls for a different mechanical strategy.

The patient cannot safely take DAPT. A stent that cannot be protected with adequate antiplatelet therapy is a stent that cannot be safely placed. In patients with upcoming surgery, very high bleeding risk, or barriers to reliable medication adherence, medical therapy or bypass surgery may be the safer path.

If you are wondering why a doctor would not put a stent in, it is crucial to recognize that they are not withholding treatment. In stable disease, the core alternative is optimized medical therapy with structured follow-up — which extensive clinical trial data demonstrates provides equivalent long-term event protection in most stable patients. Guideline-directed medical therapy is an active, highly effective treatment path.

---

Types of Stents: Drug-Eluting Stent vs. Bare-Metal Stent

When evaluating a drug eluting stent vs bare metal stent, drug-eluting stents (DES) represent the modern standard of care. A DES consists of a metallic scaffold coated with an antiproliferative medication that elutes slowly over weeks to months, actively inhibiting the cellular regrowth (neointimal hyperplasia) that would otherwise narrow the treated arterial lumen. Contemporary DES have dramatically better restenosis rates than older designs and excellent long-term durability in most settings.[10,12]

Bare metal stents (BMS) are the original design — metal without drug coating. They are rarely used today because DES are superior for restenosis without meaningful safety disadvantage in most situations. Residual indications include anticipated surgery requiring very short DAPT duration, or significant bleeding risk where drug-eluting coatings are a concern.[9]

Bioresorbable scaffolds were designed to dissolve over time, leaving no permanent implant. Early iterations showed higher adverse event rates than contemporary DES; their use declined significantly.[13] Research on improved designs continues.

The choice of stent type is a clinical and technical decision made by the operator based on vessel size, lesion length, calcification, and individual patient factors. Most patients will receive a contemporary DES.

---

What Happens During a Heart Stent Procedure?

Before the procedure: Teams review kidney function (contrast dye can affect renal function), bleeding risk, and current medications. Pre-procedure hydration strategies reduce contrast-associated kidney injury in at-risk patients.

Access: A small puncture enters an artery — most commonly the radial artery at the wrist. Radial access is preferred in most settings because it is associated with lower access-site bleeding, faster mobilisation, and earlier discharge compared to femoral (groin) access — advantages that are most pronounced in ACS populations.[14]

Angiography: Contrast dye is injected while X-ray imaging captures real-time images of blood flowing through the coronary arteries, creating a map of narrowings and flow.

Physiologic assessment (when indicated): A pressure-sensing wire measures FFR or iFR across a narrowing to determine whether it is genuinely impeding blood flow. This separates anatomically impressive lesions from functionally significant ones. Stenting a lesion that is not flow-limiting adds risk without benefit.[15]

Intravascular imaging (when indicated): IVUS (intravascular ultrasound) or OCT (optical coherence tomography) provides images from inside the artery wall — not just its silhouette — enabling precise stent sizing, optimisation of expansion, and identification of underlying plaque structure. Randomised data support better outcomes with IVUS guidance in selected complex PCI settings.[16,17]

Lesion preparation: Heavily calcified lesions may need modification before a stent can fully expand. Calcium modification tools include rotational atherectomy, intravascular lithotripsy, and specialised balloons.

Stent deployment: The stent, crimped onto a deflated balloon, is positioned at the lesion and expanded. The balloon is removed; the stent remains.

Optimisation: Additional balloon inflations confirm that the stent is fully expanded and well-apposed to the vessel wall. Underexpansion and malapposition increase the risk of stent thrombosis.

Final angiography: Confirms adequate blood flow through the stented segment.

After the final stages of the heart stent procedure: Radial access allows patients to sit up immediately; a specialized compression band prevents access-site bleeding and is slowly deflated over several hours. Most elective radial PCI cases are safely discharged on the same day. Femoral access requires several hours of flat bed rest. Patients treated for heart attack typically stay 2–4 days depending on MI size, complications, and institutional protocol.

---

What the Procedure and Recovery Experience Feels Like

What you may feel during the procedure:

Access site: a brief sting or pressure during local anaesthetic and arterial puncture. Catheter movement through arteries: usually nothing — arteries have no internal pain receptors. Contrast injection: brief warmth or flushing, sometimes a sensation of needing to urinate — harmless and brief. Balloon inflation: brief chest pressure or tightness as the artery is temporarily occluded — resolves within seconds when the balloon deflates. After the procedure: access site soreness, mild fatigue from sedation, occasionally mild nausea.

Emergency PCI: Patients describe being swept into a process they did not choose — everything moving faster than they could process, strangers working on their heart, limited time to understand what was happening. Many have limited recall of the procedure itself due to sedation. Clarity and full understanding often come later, after the acute phase has passed. This is not a failure of communication — in STEMI care, the priority is opening the artery. The conversation follows once the patient is safe.

Elective PCI: More deliberate. Consent discussions are more detailed. The procedure itself is often less dramatic than patients anticipated — sedation keeps most people comfortable, and many have surprisingly limited recall. The most common description from patients who had significant expectations of severity: “less than I expected.”

---

Risks and Side Effects of Heart Stents: Procedural, Early, and Late

Evaluating the Risks and Side Effects of Heart Stents requires stratifying potential complications into procedural, early, and late phases. While minor issues like access site bruising or transient soreness are common, rare but severe adverse clinical events require strict post-procedural vigilance.

Procedural complications:

Access site: Bruising and soreness are normal and expected. More significant access-site bleeding — rapidly expanding swelling, a tense lump, numbness or colour change in the hand or foot — requires prompt evaluation. Radial access is associated with lower access-site complication rates than femoral in randomised comparisons.[14]

Contrast-associated kidney injury: The contrast dye used in angiography can transiently impair kidney function, particularly in patients with pre-existing kidney disease, diabetes, or poor haemodynamics. Risk is minimised by reducing contrast volume and using hydration strategies.

Coronary complications: Dissection of the artery lining, perforation, or compromise of a side branch are uncommon but possible. Most dissections are treatable with additional stenting; perforations are rare but potentially serious.

Stroke: Rare but serious. Risk is higher in older patients and those with significant aortic atherosclerosis.

Death: In-hospital mortality is very low for elective, stable PCI and substantially higher for emergency MI — especially when complicated by cardiogenic shock. These represent different clinical realities, not differences in operator skill.[35]

Why emergency PCI carries higher risk. The patient’s condition is fundamentally different: ongoing ischaemia, thrombotic burden in the artery, potential haemodynamic instability, arrhythmia vulnerability. The procedure is technically identical; the substrate is not. Emergency and elective PCI mortality figures should never be directly compared as if they represent the same procedure in the same patient.

Early post-discharge complications:

Stent thrombosis — covered in detail in the next section — is the most important early complication to prevent and understand.

Access site problems that develop at home: bruising that expands rapidly, a tense swelling, or limb colour/temperature changes warrant urgent evaluation (see Warning Signs).

Late complications:

Restenosis — gradual re-narrowing from scar tissue growth — typically presents over weeks to months with gradual return of angina symptoms. In the modern DES era, clinically significant restenosis requiring repeat intervention occurs in the low single digits in the first year in straightforward cases, though rates are higher with diabetes, small vessels, long lesions, and complex anatomy.[10,11]

Disease progression elsewhere — symptoms returning after a technically successful stent may reflect new disease developing at other locations, not failure of the stent itself. The underlying disease process did not stop at the stent edges.

---

Stent Thrombosis: Why DAPT Exists

Stent thrombosis is the complication that earns more clinical respect than almost any other in interventional cardiology — not because it is common, but because of what happens when it does occur.

What it is. A coronary stent, before the metal surface is covered by healed arterial lining, presents a foreign surface that actively promotes platelet aggregation and clot formation. If a clot forms within the stent, it occludes the artery suddenly and completely — typically presenting as a large myocardial infarction with significant short-term mortality.[18,19]

How common it is. With contemporary DES and consistent antiplatelet therapy, definite stent thrombosis occurs in under 1% of patients at one year in most modern datasets. The risk is front-loaded — highest in the first days to weeks after implantation, declining over time. It is higher after ACS than elective PCI, higher with underexpansion or malapposition, higher with diabetes and chronic kidney disease, and substantially higher when antiplatelet therapy is interrupted.[18,19,20]

This is the biology that makes DAPT important. The healing of arterial lining across stent struts is a time-dependent biological process. During the period before that healing is complete, the stent surface is thrombogenic. Antiplatelet therapy — aspirin plus a P2Y12 inhibitor — suppresses this clotting tendency by blocking platelet activation pathways that would otherwise operate on the exposed metal.

Interrupting that suppression prematurely exposes the healing stent surface to platelet activation. This is why cardiologists treat antiplatelet interruption decisions after stenting carefully — it is a clinical judgement based on the biology of healing, not an administrative rule.

How stent thrombosis usually happens — and it is usually preventable:

The most common pathways are not patient carelessness but systems failures:

A prescription lapses due to prior authorisation delays, insurance problems, or cost. The patient cannot keep medications down because of vomiting or illness. Another clinician — a dentist, surgeon, or urgent care provider — advises stopping “blood thinners” without knowing a stent was recently placed. A hospital admission results in home medications being “held” or omitted during routine medication reconciliation.

Any of these situations — within the first year after stenting, and especially in the first months — is a cardiology coordination issue, not something to handle independently. Call the team that manages the stent.

---

Medications After Stenting: Dual Antiplatelet Therapy After a Drug-Eluting Stent

Dual antiplatelet therapy (DAPT): Aspirin plus a P2Y12 inhibitor — clopidogrel, ticagrelor, or prasugrel — is the foundation of post-stent anticoagulation. The duration is individualised based on the clinical context (ACS versus elective stenting), bleeding risk, ischaemic risk, stent characteristics, and patient factors.

Agent	Key Features
Clopidogrel	Once daily; requires liver activation; variable response; widely available generically
Ticagrelor	Direct-acting; more consistent inhibition; twice daily; may cause transient dyspnoea
Prasugrel	Most potent; higher bleeding risk; avoid with prior stroke/TIA; once daily

Agent characteristics per 2023 AHA/ACC Chronic Coronary Disease guideline and 2025 ACS guidelines.[21]

DAPT duration: After ACS, longer durations (typically 12 months) are the default, with adjustment based on bleeding risk.[21] After elective PCI for stable disease, shorter durations are supported in appropriate candidates.[22,23] Some high-risk patients — prior MI, diabetes, multivessel disease — may benefit from extended DAPT beyond the initial course, accepting higher bleeding risk for reduced thrombotic events.[24] Duration decisions belong to the clinical team; they are not a clock that simply runs out.

The central tradeoff every DAPT decision reflects: more antiplatelet intensity reduces thrombotic risk and increases bleeding risk. Two patients with identical stents may have different DAPT durations because their bleeding risk profiles differ — not because the evidence is inconsistent.

Antiplatelet vs anticoagulant — an important distinction. Post-stent antiplatelets (aspirin, clopidogrel, etc.) inhibit platelet function. Anticoagulants (warfarin, apixaban, rivaroxaban) affect the coagulation cascade. These are different mechanisms, different medications, and not interchangeable. Some patients require both — for example, those with atrial fibrillation who receive a stent — creating “triple therapy” regimens that require careful bleeding-thrombosis balancing and cardiology guidance.[26]

What to do if doses are missed: In the first year after stenting — particularly the first months — a missed P2Y12 dose is a cardiology coordination issue. If you cannot take antiplatelet medications due to vomiting, surgery, cost, or another clinician’s instruction, contact the cardiology team managing your stent before stopping. This is not about asking permission; it is about ensuring someone who understands your stent timing is part of the decision.

Foundation medical therapy: Beyond DAPT, post-PCI care includes high-intensity statin therapy for plaque stabilisation and LDL reduction,[25] blood pressure control, and other agents based on individual clinical features. The medications that address the systemic biology — statins, ACE inhibitors or ARBs, agents for diabetes — remain the most important determinants of long-term prognosis. A stent changes the anatomy; these medications address the biology that determines what happens over the next decade.

---

Restenosis and Recurrent Symptoms: Managing Chest Pain After a Stent

Restenosis is gradual re-narrowing at the stented site, driven by the body’s healing response — scar tissue and smooth muscle cells growing over the stent struts, occasionally excessively. It is biologically distinct from the original atherosclerotic disease: restenosis is a healing response to mechanical injury, not plaque formation. It presents gradually over weeks to months as a return of angina symptoms — not as a sudden event. In the contemporary DES era, clinically significant restenosis requiring repeat intervention occurs in the low single digits in uncomplicated cases; rates are higher with diabetes, small vessels, long lesions, and bifurcations.[10,11]

Disease progression elsewhere accounts for a substantial portion of symptoms returning after technically successful PCI. The atherosclerosis that produced the treated lesion continues developing throughout the coronary tree. New narrowings can develop adjacent to the stent, in other vessels, or in segments that appeared normal on the original angiogram. Returning symptoms do not necessarily mean the stent failed.

When symptoms persist despite a “successful” stent. Some patients continue to have chest discomfort despite good blood flow on angiography. This is frustrating and requires systematic evaluation — not the assumption that something went wrong. Possible explanations include diffuse disease not fully addressed by the stented segment, microvascular angina (disease in the small vessels too fine for stents to reach), coronary vasospasm, incomplete revascularisation of other significant vessels, or non-cardiac causes — musculoskeletal pain, oesophageal disorders, anxiety.

A technically normal post-stent angiogram does not guarantee symptom resolution. The cardiologist’s job when symptoms persist is not to confirm the procedure worked, but to identify what is still causing the patient’s symptoms.

---

Heart Bypass Surgery vs. Stents: Choosing the Right Revascularization Strategy

For patients with multi-vessel coronary disease, both PCI and coronary artery bypass grafting (CABG) may be appropriate options. These are genuinely different revascularisation strategies — not just different degrees of the same intervention.

A stent mechanically opens a focal narrowing and is supported by antiplatelet therapy during healing. CABG creates entirely new conduits — arterial and vein grafts that route blood around diseased segments, bypassing not just focal obstructions but entire diseased arterial lengths. In complex disease with diffuse narrowings or diabetes, the durability advantage of CABG reflects this: you are not just opening one segment, you are routing around the diseased portion entirely.

When PCI is generally favoured: one or two vessel disease with favourable anatomy, high surgical risk, patient preference to avoid open surgery, or urgent need for immediate treatment during ACS.

When CABG is generally favoured: three-vessel disease with complex anatomy, significant left main involvement, reduced left ventricular function, diabetes with multivessel disease, or long diffuse lesions unsuitable for stenting.[27,28,30]

Key evidence:

The SYNTAX trial compared PCI to CABG in patients with three-vessel or left main disease. As anatomical complexity increased (measured by SYNTAX score), CABG outcomes progressively exceeded PCI outcomes.[30]

The FREEDOM trial studied diabetic patients with multivessel disease. CABG significantly reduced death and MI compared to PCI over follow-up — an outcome difference attributed to the more complete revascularisation that bypass surgery provides across diffuse diabetic coronary disease, though the precise mechanisms are not fully established.[27]

The EXCEL and NOBLE trials studied left main disease and reached somewhat differing conclusions, partly due to differences in how periprocedural events were counted and follow-up duration.[31,32] This divergence reinforces why heart-team discussion — not any single trial — should guide left main decisions.

The Heart Team approach. For complex coronary disease where both options are reasonable, guidelines recommend that an interventional cardiologist, cardiac surgeon, and the patient discuss the options together before a decision is made.[33] This is not bureaucratic procedure. It ensures that both a PCI-skilled and a surgery-skilled perspective evaluates the anatomy, that the patient understands the genuine tradeoffs, and that the recommendation reflects the full picture rather than the perspective of whoever was consulted first.

Why two cardiologists may recommend different strategies. In complex cases, reasonable clinicians can reach different conclusions — they may weight symptom burden, anatomy, surgical risk, or patient preferences differently. The evidence base for many intermediate situations is genuinely ambiguous. This reflects the complexity of the biology, not error or uncertainty by individual physicians.

Why you might wake from a diagnostic angiogram without a stent placed. When complex anatomy makes both PCI and CABG potentially reasonable, the decision should not be made while the patient is sedated on the table. Proceeding with stenting before a full heart-team evaluation, when CABG might be superior, deprives the patient of a potentially better outcome. Waking up without a stent placed is sometimes the most careful care.

---

Left Main and Complex Disease

The left main coronary artery is the trunk that supplies the left anterior descending and circumflex arteries — together supplying the majority of the left ventricular myocardium. Significant narrowing of the left main (≥50%) is high-risk anatomy: compromise of this vessel threatens a large territory of muscle simultaneously.

ISCHEMIA specifically excluded left main disease because revascularisation has clearer prognostic benefit in this anatomy — the stable-CAD-treat-medically principle does not extend cleanly to left main disease. Both PCI and CABG are established revascularisation options for left main disease. The SYNTAX, EXCEL, and NOBLE trials provide outcome data across anatomical subgroups, with the consensus being that simpler left main anatomy has more comparable PCI/CABG outcomes while complex left main disease with multivessel involvement generally favours CABG.[30,31,32] Heart-team discussion is particularly important.

---

Complete vs Culprit-Only Revascularisation

In patients who have a heart attack and are found to have multivessel disease — significant narrowings in additional vessels beyond the artery causing the MI — an important question arises: treat only the culprit artery acutely, or also address the other vessels?

The COMPLETE trial demonstrated that staged complete revascularisation — treating the culprit artery during the acute MI and returning to treat other significant lesions days to weeks later — reduced subsequent cardiovascular events compared with culprit-only treatment in haemodynamically stable patients.[29] This is now a standard evidence-based approach for appropriate candidates.

Complete revascularisation is a deliberate staged strategy, not a decision made during the emergency phase. It requires stable physiology, adequate renal function, and assessment of whether non-culprit lesions are genuinely significant.

---

Recovery Time After a Heart Stent Procedure and Cardiac Rehabilitation

Recovery after elective PCI with radial access is generally rapid — most patients return to normal activities within days and full activity within one to two weeks. The access site heals; the stent heals; the medications are established.

Recovery after MI is more substantial and reflects myocardial healing, not just the puncture site. Fatigue, reduced stamina, and emotional impact can persist for weeks. The timeline is shaped by the extent of muscle injury, complications, ventricular function, and how medications are optimised.

Cardiac rehabilitation is one of the most evidence-based and underutilised interventions in post-MI and post-PCI care. A large contemporary meta-analysis of randomised trials found that exercise-based cardiac rehabilitation is associated with lower cardiovascular mortality, fewer hospitalisations, and improved quality of life compared with usual care.[40] Beyond fitness, cardiac rehab improves medication adherence, risk factor control, and patient confidence in returning to activity. If eligible, completing the full programme matters more than just starting it.

Follow-up testing after PCI is symptom-driven in most patients. Routine surveillance imaging in asymptomatic patients has not consistently shown benefit and is not routinely recommended.[34]

Keeping stent information accessible. Other clinicians who manage future procedures, surgical planning, or emergency care need to know: that a stent is present, when it was placed, and what antiplatelet regimen is current. This information should be carried — in a wallet, on a phone, or on a card — because it directly affects how other clinicians make medication and procedural decisions.

---

What Patients Often Misunderstand After Stenting

These misunderstandings are common — and almost always arise from explanations that did not happen clearly at discharge, not from patients failing to pay attention. They deserve direct address:

“The blockage is fixed, so the disease is gone.” The stent opened one segment. The systemic biology that produced that plaque — and is producing plaques throughout the coronary tree — is unchanged. Medications and risk factor management are the ongoing treatment of the actual disease.

“I can stop my medications now that I feel better.” The medications are not treating symptoms. They are modifying the biology that determines future events. Stopping statins when LDL is “normal” removes the protection that produced the normal number. Stopping antiplatelets early after a stent exposes a healing metal surface to clotting biology.

“Another artery can’t cause trouble — only the one they fixed.” Future events frequently arise from plaques in other segments, not from the treated vessel. This is the core insight from PROSPECT and from the systemic biology framework.

“No symptoms means no danger.” Some of the most dangerous coronary anatomy — significant left main disease, severe multivessel disease — can exist with minimal symptoms.

“The procedure failed because my symptoms returned.” Returning symptoms may reflect restenosis, progression elsewhere, microvascular disease, or non-cardiac causes. Systematic evaluation identifies the cause. Assuming procedural failure is usually the wrong interpretation.

---

Warning Signs of Stent Thrombosis and Post-Procedure Complications

Call emergency services immediately for:

Chest pain or pressure — especially if similar to pre-stent symptoms, at rest, severe, or lasting more than a few minutes. Radiation to arm, jaw, neck, or back. Sudden breathlessness. Sweating, nausea, or light-headedness with chest symptoms. Hand or foot suddenly cold, pale, numb, or discoloured (after access from wrist or groin). Uncontrolled bleeding from access site. Rapidly expanding or tense swelling at access site.[36,37]

Contact your cardiology team promptly (same day or next business day) for:

Gradual return of exertional symptoms similar to pre-stent angina. Slowly expanding bruise at access site (not tense, not rapidly growing). Medication side effects — gum bleeding, bruising, gastrointestinal upset. New symptoms that concern you but do not fit an acute ischaemic pattern.

When in doubt — call emergency services. No one will criticise caution after a cardiac procedure. The cost of an unnecessary emergency visit is a few hours. The cost of a missed stent thrombosis can be irreversible.

---

Common Questions About Post-Stent Care

What about NSAIDs? Some NSAIDs — particularly ibuprofen taken around the same time as aspirin — can blunt aspirin’s antiplatelet effect, and NSAIDs as a class have been associated with increased cardiovascular risk. The FDA has specifically flagged the ibuprofen-aspirin interaction.[38] Many clinicians recommend avoiding regular NSAID use after stenting; paracetamol (acetaminophen) is generally preferred for pain. Discuss this with your care team.

When can I resume sexual activity? The Princeton IV consensus frames this around functional capacity and cardiovascular risk category rather than a universal timeline. Sexual activity with a usual partner is roughly equivalent to moderate exertion — comparable to briskly climbing two flights of stairs. If you can do that without symptoms, activity is generally considered low risk.[39] After uncomplicated elective PCI, most patients can resume within days. After MI, timing depends on myocardial recovery — your cardiology team’s guidance applies.

Will I need more stents in the future? Possibly. Coronary artery disease can progress, and new narrowings can develop elsewhere over time. Whether this happens depends significantly on how well risk factors and medications are managed long-term.

What about MRI and airport screening? Most contemporary coronary stents are MRI-conditional, and most patients can undergo MRI without concern — but specific timing and scanner settings should follow implant documentation. Airport metal detectors and body scanners do not affect stents. Device compatibility questions are addressed by carrying the stent implant card.

What about surgery or dental work? Any planned procedure that involves stopping antiplatelet medications requires cardiology coordination — especially within the first year after stenting. Many procedures can proceed on aspirin without P2Y12 interruption; decisions about P2Y12 interruption are risk-stratified by time since stenting and procedural bleeding risk.

Travel after PCI? After uncomplicated elective PCI, flying is generally possible within a few days to a week. After MI, the typical guidance is 3–10 days for uncomplicated cases, 4–6 weeks for more significant events.[41] Travel plans — particularly international — should be discussed with your team.

---

Stent Information to Keep Accessible

This information is needed by other clinicians for safe procedure planning and emergency decisions. Keep it in a wallet, on your phone, or both.

The essential sentence to carry: “I have a coronary stent placed on [DATE] for [elective stable angina / heart attack]. Current antiplatelet medications: [NAMES]. My P2Y12 inhibitor is planned until [DATE or INDEFINITE]. My cardiologist is [NAME] at [PHONE].”

The indication — elective vs heart attack — matters because it shapes how other clinicians assess urgency if you need a procedure or present to an emergency department.

Additional useful information: artery treated, stent type if known, known drug allergies, emergency contact.

---

Questions to Ask Before and After Stenting

Before the procedure: “Is this stent for symptom relief, or is there prognostic benefit in my specific situation?” “What are the alternatives — including medical therapy alone or bypass surgery?” “Has a heart team discussed my case, particularly if I have multivessel or left main disease?” “Is the blockage confirmed to be flow-limiting by physiologic testing?”

After the procedure: “Which arteries were treated, and what type of stent was used?” “How long do I need dual antiplatelet therapy?” “What symptoms should prompt emergency care?” “When can I return to driving, work, exercise, and travel?” “Am I a candidate for cardiac rehabilitation?”

Ongoing: “Is my LDL at goal? Are my other medications optimised?” “Are there remaining blockages that might need attention?” “What does long-term follow-up look like?”

---

What Success Looks Like

Success after coronary stenting does not usually feel dramatic. For many patients, it is the absence of events — the heart attack that did not occur, the angina that did not return, the decade of normal function that followed.

Medicine that prevents catastrophe is psychologically invisible. The statin that stabilised a vulnerable plaque does not produce a memorable sensation. The antiplatelet therapy that prevented a stent from clotting in the first year will never be experienced as the crisis it averted. Patients who adhere to their regimen, manage their risk factors, attend cardiac rehabilitation, and return for follow-up may feel no different in daily life from what they would have felt doing nothing — until, over years, the outcomes diverge.

This is why understanding the biology matters as much as understanding the procedure. A stent is a powerful, targeted tool — lifesaving in the right situation, symptom-transforming in others. It addresses one part of a larger disease. The biology that created the problem, and that continues throughout the rest of the coronary tree, is addressed by medications, lifestyle, and long-term risk management.

Needing a stent is not a personal failure. Coronary artery disease develops over decades through a combination of genetic susceptibility, accumulated risk factor exposure, and biological processes that are often well-established before any symptoms appear. Many people who live exemplary lives — exercising regularly, eating well, never smoking — still develop coronary disease because their genetics, lipid biology, or inflammatory profile made it likely. A stent is a response to that biology. It is not a verdict on how someone lived.

Long-term protection comes from treating the systemic disease: lipid lowering, blood pressure control, diabetes management, smoking cessation, physical activity, adherence to antiplatelet therapy, and cardiac rehabilitation. These are not lifestyle suggestions appended to the real treatment. They are the real treatment — for the part of the disease that determines most of what happens over the next twenty years.

A coronary angiogram is not a map of good arteries and bad arteries. It is a snapshot of one dimension — focal anatomy — of a multidimensional disease involving plaque biology throughout the vascular system, systemic inflammation, metabolic dysfunction, thrombosis risk, and decades of cumulative exposure. Understanding that is understanding coronary artery disease.

---

Key Terms

ACS (Acute coronary syndrome): Unstable angina, NSTEMI, or STEMI — conditions caused by acute plaque disruption and thrombosis.

Angiography: X-ray imaging of blood vessels using injected contrast dye; shows the silhouette of the vessel lumen but not the vessel wall or plaque biology.

CABG (Coronary artery bypass grafting): Surgery creating new conduits to route blood around blocked arteries, using arterial or vein grafts.

DAPT (Dual antiplatelet therapy): Aspirin plus a P2Y12 inhibitor — standard antiplatelet regimen after coronary stenting.

Drug-eluting stent (DES): A metal stent coated with antiproliferative medication to reduce restenosis.

FFR (Fractional flow reserve) / iFR (Instantaneous wave-free ratio): Pressure-based measurements that determine whether a coronary narrowing is actually restricting blood flow; used to guide stenting decisions in stable disease.

IVUS / OCT (Intravascular ultrasound / Optical coherence tomography): Catheter-based imaging from inside the artery, used to optimise stent placement and assess plaque structure.

PCI (Percutaneous coronary intervention): Catheter-based coronary treatment including balloon angioplasty and stenting; performed through a small puncture in the wrist or groin.

Restenosis: Gradual re-narrowing at a treated site due to the body’s healing response — biologically distinct from the original atherosclerotic disease.

Stable angina: Predictable chest discomfort occurring with exertion and resolving with rest, caused by reduced blood flow through a narrowed coronary artery during increased demand.

STEMI (ST-elevation myocardial infarction): The most severe heart attack pattern — typically caused by complete, abrupt coronary occlusion.

Stent thrombosis: Clot formation within a stent before the metal surface is covered by healed arterial tissue; presents as abrupt occlusion, often as a large MI. Antiplatelet interruption is the primary modifiable risk factor.

SYNTAX score: An angiographic scoring system grading coronary anatomy complexity; higher scores favour CABG over PCI for revascularisation.

---

References

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13–20. https://doi.org/10.1016/S0140-6736(03)12113-7
2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393
3. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48(7):1319–1325. https://doi.org/10.1016/j.jacc.2006.06.050
4. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64(24):e139–e228. https://doi.org/10.1016/j.jacc.2014.09.017
5. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease (COURAGE). N Engl J Med. 2007;356(15):1503–1516. https://doi.org/10.1056/NEJMoa070829
6. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA). N Engl J Med. 2020;382(15):1395–1407. https://doi.org/10.1056/NEJMoa1915922
7. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391(10115):31–40. https://doi.org/10.1016/S0140-6736(17)32714-9
8. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis (PROSPECT). N Engl J Med. 2011;364(3):226–235. https://doi.org/10.1056/NEJMoa1002358
9. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331(8):496–501. https://doi.org/10.1056/NEJM199408253310802
10. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368(3):254–265. https://doi.org/10.1056/NEJMra1115400
11. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. Heart. 2014;100(2):153–159. https://doi.org/10.1136/heartjnl-2013-304933
12. Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65(23):2496–2507. https://doi.org/10.1016/j.jacc.2015.04.011
13. Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease. Lancet. 2017;390(10096):760–772. https://doi.org/10.1016/S0140-6736(17)31368-X
14. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL). Lancet. 2011;377(9775):1409–1420. https://doi.org/10.1016/S0140-6736(11)60404-2
15. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease (FAME 2). N Engl J Med. 2012;367(11):991–1001. https://doi.org/10.1056/NEJMoa1205361
16. Hong SJ, Mintz GS, Ahn CM, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation (IVUS-XPL). JACC Cardiovasc Interv. 2020;13(1):62–71. https://doi.org/10.1016/j.jcin.2019.09.033
17. Räber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. Eur Heart J. 2018;39(35):3281–3300. https://doi.org/10.1093/eurheartj/ehy285
18. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011;123(16):1745–1756. https://doi.org/10.1161/CIRCULATIONAHA.110.981688
19. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53(16):1399–1409. https://doi.org/10.1016/j.jacc.2008.12.055
20. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents. JACC Cardiovasc Interv. 2013;6(12):1267–1274. https://doi.org/10.1016/j.jcin.2013.06.015
21. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771–e862. https://doi.org/10.1161/CIR.0000000000001309
22. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events (STOPDAPT-2). JAMA. 2019;321(24):2414–2427. https://doi.org/10.1001/jama.2019.8145
23. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI (TWILIGHT). N Engl J Med. 2019;381(21):2032–2042. https://doi.org/10.1056/NEJMoa1908419
24. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction (PEGASUS-TIMI 54). N Engl J Med. 2015;372(19):1791–1800. https://doi.org/10.1056/NEJMoa1500857
25. Cannon CP, Braunwald E, Murphy SA, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT-TIMI 22). N Engl J Med. 2004;350(15):1495–1504. https://doi.org/10.1056/NEJMoa040583
26. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation (AUGUSTUS). N Engl J Med. 2019;380(16):1509–1524. https://doi.org/10.1056/NEJMoa1817083
27. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes (FREEDOM). N Engl J Med. 2012;367(25):2375–2384. https://doi.org/10.1056/NEJMoa1211585
28. Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372(13):1213–1222. https://doi.org/10.1056/NEJMoa1412168
29. Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction (COMPLETE). N Engl J Med. 2019;381(15):1411–1421. https://doi.org/10.1056/NEJMoa1907775
30. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease (SYNTAX). N Engl J Med. 2009;360(10):961–972. https://doi.org/10.1056/NEJMoa0804626
31. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease (EXCEL). N Engl J Med. 2016;375(23):2223–2235. https://doi.org/10.1056/NEJMoa1610227
32. Mäkikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE). Lancet. 2016;388(10061):2743–2752. https://doi.org/10.1016/S0140-6736(16)32052-9
33. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394
34. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease. J Am Coll Cardiol. 2017;69(17):2212–2241. https://doi.org/10.1016/j.jacc.2017.02.001
35. Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010;55(18):1923–1932. https://doi.org/10.1016/j.jacc.2010.02.005
36. American Heart Association. Warning Signs of a Heart Attack. heart.org. Accessed January 2026. https://www.heart.org/en/health-topics/heart-attack/warning-signs-of-a-heart-attack
37. NHS. Heart attack — call 999 immediately if you think you or someone else is having a heart attack. nhs.uk. Accessed January 2026. https://www.nhs.uk/conditions/heart-attack/
38. US Food and Drug Administration. Concomitant Use of Ibuprofen and Aspirin: Potential for Attenuation of the Anti-Platelet Effect of Aspirin. fda.gov. Published September 2006. https://www.fda.gov/drugs/drug-safety-and-availability/concomitant-use-ibuprofen-and-aspirin
39. Kloner RA, Burnett AL, Miner M, et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J Sex Med. 2024;21(2):90–116. https://doi.org/10.1093/jsxmed/qdad157
40. Dibben GO, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J. 2023;44(6):452–469. https://doi.org/10.1093/eurheartj/ehac572
41. Driver and Vehicle Licensing Agency (DVLA). Assessing fitness to drive: a guide for medical professionals. UK Government; 2020. https://www.gov.uk/guidance/cardiovascular-disorders-assessing-fitness-to-drive